We performed allogeneic bone-marrow transplantation of normal cells in an eight-year-old patient with Type 3 Gaucher's disease in an attempt to alter his progressive deterioration. The procedure resulted in complete engraftment of the enzymatically normal donor cells. Donor monocyte precursors were present in the circulation of the recipient by 28 days after transplantation. Post-transplantation beta-glucocerebrosidase activity in mononuclear white cells in peripheral blood exceeded normal levels. Despite these early results no change in Gaucher's-cell infiltration of the bone marrow was noted for at least 111 days, and Gaucher's cells persisted in the marrow for at least 274 days. The plasma glucocerebroside concentration ultimately returned to normal. During the post-transplantation course, until the patient died from an episode of sepsis, there was no important change in his clinical status. However, this case demonstrates that the enzymatic abnormality in hematopoietic cells in Gaucher's disease is correctable by bone-marrow transplantation, leading to normalization of plasma levels of glucocerebroside. We observed the long survival of Gaucher's cells, which was consistent with the lack of clinical improvement. Intervention might have been more effective earlier in the course of the disease.
This article has been cited by other articles:
Sanchez, R., Etzell, J., Kim, G., Packman, S., Fairley, C., Goldsby, R.
(2005). Pediatric Malignancies: CASE 2. Peripheral T-Cell Lymphoma in an Adolescent With Unsuspected Gaucher Disease. JCO
23: 4792-4793
[Full Text]
Goker-Alpan, O, Hruska, K S, Orvisky, E, Kishnani, P S, Stubblefield, B K, Schiffmann, R, Sidransky, E
(2005). Divergent phenotypes in Gaucher disease implicate the role of modifiers. J. Med. Genet.
42: e37-e37
[Abstract][Full Text]
Weinberg, K. I.
(2005). Early Use of Drastic Therapy. NEJM
352: 2124-2126
[Full Text]
Sullivan, K. M., Parkman, R., Walters, M. C.
(2000). Bone Marrow Transplantation for Non-Malignant Disease. ASH Education Book
2000: 319-338
[Abstract][Full Text]
Lorincz, M., Herzenberg, L. A., Diwu, Z., Barranger, J. A., Kerr, W. G.
(1997). Detection and Isolation of Gene-Corrected Cells in Gaucher Disease Via a Fluorescence-Activated Cell Sorter Assay for Lysosomal Glucocerebrosidase Activity. Blood
89: 3412-3420
[Abstract][Full Text]
Armitage, J. O.
(1994). Bone Marrow Transplantation. NEJM
330: 827-838
[Full Text]
Brady, R. O., Barton, N. W., Grabowski, G. A.
(1993). The Role of Neurogenetics in Gaucher Disease. Arch Neurol
50: 1212-1224
[Abstract]
Sidransky, E., Ginns, E. I.
(1993). Clinical Heterogeneity Among Patients With Gaucher's Disease. JAMA
269: 1154-1157
[Abstract]
Beutler, E
(1992). Gaucher disease: new molecular approaches to diagnosis and treatment. Science
256: 794-799
[Abstract]
Hoogerbrugge, P., Suzuki, K, Suzuki, K, Poorthuis, B., Kobayashi, T, Wagemaker, G, van Bekkum, D.
(1988). Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science
239: 1035-1038
[Abstract]
Percy, A. K.
(1987). Review Article: The Inherited Neurodegenerative Disorders of Childhood: Clinical Assessment. J Child Neurol
2: 82-97
[Abstract]
Bieber, F. R., Mortimer, G., Kolodny, E. H., Driscoll, S. G.
(1986). Pathologic Findings in Fetal GM1 Gangliosidosis. Arch Neurol
43: 736-738
[Abstract]
Parkman, R
(1986). The application of bone marrow transplantation to the treatment of genetic diseases. Science
232: 1373-1378
[Abstract]
Sorge, J., Kuhl, W., West, C., Beutler, E.
(1986). Gaucher Disease: Retrovirus-mediated Correction of the Enzymatic Defect in Cultured Cells. Cold Spring Harb Symp Quant Biol
51: 1041-1046
[Abstract]
Choudary, P.V., Tsuji, S., Martin, B.M., Guild, B.C., Mulligan, R.C., Murray, G.J., Barranger, J.A., Ginns, E.I.
(1986). The Molecular Biology of Gaucher Disease and the Potential for Gene Therapy. Cold Spring Harb Symp Quant Biol
51: 1047-1052
[Abstract]
Alroy, J, Orgad, U, Ucci, A., Schelling, S., Schunk, K., Warren, C., Raghavan, S., Kolodny, E.
(1985). Neurovisceral and skeletal GM1-gangliosidosis in dogs with beta-galactosidase deficiency. Science
229: 470-472
[Abstract]
Previous
